bms-214662

Small moleculeexperimental

Chemistry & pharmacology

Loading structure…

SMILES

N#Cc1ccc2c(c1)CN(S(=O)(=O)c1cccs1)[C@H](Cc1ccccc1)CN2Cc1c[nH]cn1
Mol. weight
489.63 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 7-cyano-2,3,4,5-tetrahydro-1-(1h-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1h-1,4-benzodiazepine
  • bms 214662
  • bms-214662
  • bms-214662
  • bms-214662
  • bms-214662

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00022529Phase 1Jul 1, 2001National Cancer Institute (NCI), Temple University
NCT00006018Phase 1Jul 1, 2000Case Western Reserve University, National Cancer Institute (NCI)
NCT00006242Phase 1Jul 1, 2000Harvard University, National Cancer Institute (NCI)
NCT00005973Phase 1Apr 1, 2000National Cancer Institute (NCI), University of Texas at Houston
NCT00006213Phase 1Apr 1, 2000National Cancer Institute (NCI), University of Texas at Houston
NCT00004877Phase 1Jul 1, 1999Cornell University, National Cancer Institute (NCI)
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government6411999
University of Texas at HoustonAcademic/Hospital2012000
Case Western Reserve UniversityAcademic/Hospital1112000
Cornell UniversityAcademic/Hospital1111999
Harvard UniversityAcademic/Hospital1012000
Temple UniversityAcademic/Hospital1012001
6 organizations
Page 1 / 1